Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy.
Int J Hyperthermia. 2021;38(1):771-776. doi: 10.1080/02656736.2021.1923837.
To assess the capability of ultrasound-computed tomography (US-CT) fusion imaging to guide a precise targeting of renal tumors invisible or poorly visible with US.
From 2016 renal tumors poorly visible or inconspicuous/invisible at US were treated at our institution with the guidance of US/CT fusion in a room equipped with CT scanner. Feasibility of the procedure, accuracy of targeting, complications, and technique efficacy were evaluated.
Of 227 patients treated from 2016 to March 2020, 91 patients (65 males and 26 females, mean age 68.5 ± 10.1 years) with 97 renal lesions (mean maximum diameter 21.6 ± 9.4 mm) inconspicuous/invisible (29/97, 29.9%) or poorly visible (68/97, 70.1%) at US underwent treatment under US-CT fusion guidance. US-CT fusion imaging guidance was always technically feasible and enabled correct targeting in 97/97/(100%) of cases. Technical success was achieved in 93/97 lesions (95.9%). Three lesions were retreated during the same ablative session, while 1 was retreated in a subsequent session. Thus, primary efficacy was achieved in one session in 96/97 (98.9%) cases and secondary efficacy in 97/97 (100%) cases.
US-CT image fusion guidance allows for a correct tumor targeting of renal tumors poorly visible or inconspicuous/invisible with US alone, with a high rate of technical success and technique efficacy.
评估超声计算机断层扫描(US-CT)融合成像引导超声显示不佳或不可见的肾脏肿瘤进行精确靶向治疗的能力。
自 2016 年以来,我们机构在配备 CT 扫描仪的房间内,使用 US/CT 融合技术对 US 显示不佳或不可见/隐匿性的肾脏肿瘤进行治疗。评估该方法的可行性、靶向准确性、并发症和技术疗效。
在 2016 年至 2020 年 3 月期间,对 227 例患者进行了治疗,其中 91 例(65 例男性,26 例女性,平均年龄 68.5±10.1 岁)的 97 个肾脏病变(平均最大直径 21.6±9.4mm)US 显示不佳或不可见(29/97,29.9%)或不可见(68/97,70.1%),采用 US-CT 融合引导下进行治疗。US-CT 融合成像引导始终具有技术可行性,可在 97/97/(100%)病例中实现正确靶向。93/97 个病变(95.9%)达到了技术成功。3 个病灶在同一消融疗程中进行了再治疗,1 个病灶在后续疗程中进行了再治疗。因此,96/97(98.9%)例在单次治疗中实现了主要疗效,97/97(100%)例在单次治疗中实现了次要疗效。
US-CT 图像融合引导可实现 US 显示不佳或不可见的肾脏肿瘤的精确靶向治疗,具有较高的技术成功率和疗效。